K. Rausch

发表

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

M. Fay, N. Hynes, Yimin Wu, 2016, PloS one.

Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.

Erin E Gabriel, Michael P Fay, O. Doumbo, 2018, The Lancet. Infectious diseases.

A Method for Producing Protein Nanoparticles with Applications in Vaccines

Yimin Wu, P. Duffy, D. Narum, 2016, PloS one.

Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.

A. Jin, Yimin Wu, D. Narum, 2013, Vaccine.

Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate

Andrea J. Radtke, A. Sher, R. Germain, 2017, Scientific Reports.

Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines

N. Tolia, T. H. Dickey, P. Scaria, 2022, iScience.

Determination of Protein Content in Alhydrogel®-Based Vaccines by O-Phthalaldehyde Assay.

K. Rausch, Daming Zhu, 2017, Methods in molecular biology.

Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines.

A. Saul, L. Miller, Laura B Martin, 2009, Vaccine.

Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.

P. Scaria, P. Duffy, D. Narum, 2020, Vaccine.

Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity

E. Fischer, P. Scaria, P. Duffy, 2017, PloS one.

Immunogenicity of Self-Associated Aggregates and Chemically Cross-Linked Conjugates of the 42 kDa Plasmodium falciparum Merozoite Surface Protein-1

C. Long, L. Miller, G. Mullen, 2012, PloS one.

Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1

J. Kurtis, M. Fried, P. Duffy, 2017, Clinical and Vaccine Immunology.

Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.

S. Hoffman, O. Doumbo, Zonghui Hu, 2021, The Lancet. Infectious diseases.

Accounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresis

L. Carter, D. Carter, C. Fox, 2017, Therapeutic advances in vaccines.

Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.

Yimin Wu, P. Duffy, D. Narum, 2017, Vaccine.

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.

A. Saul, C. Long, Yimin Wu, 2005, Vaccine.

Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria

M. Fay, Hong Zhou, J. Treanor, 2008, PloS one.

Formulation of vaccines containing CpG oligonucleotides and alum.

A. Saul, C. Long, G. Mullen, 2007, Journal of immunological methods.

Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.

Hong Zhou, A. Saul, C. Long, 2008, Vaccine.

Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.

A. Saul, C. Long, G. Mullen, 2007, Vaccine.

Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230*

X. Ambroggio, J. Sattabongkot, Yimin Wu, 2016, The Journal of Biological Chemistry.

Phase 1 Study in Malaria Naïve Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria

M. Fay, C. Long, L. Miller, 2012, PloS one.

Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice

P. Scaria, Y. Wu, B. Swihart, 2020, medRxiv.

Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure.

L. Miller, G. Mullen, Yimin Wu, 2009, Microbes and infection.

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51

M. Fay, A. Saul, C. Long, 2008, PloS one.

Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.

Mary Anne Kidwell, E. Gebregeorgis, L. Miller, 2011, Vaccine.

Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer.

E. Gebregeorgis, A. Saul, C. Long, 2012, Vaccine.

Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909

M. Fay, A. Lawrie, A. Hill, 2011, PloS one.

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

M. Fay, C. Long, L. Miller, 2010, Vaccine.

TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25

A. Weiner, C. Long, M. Juraska, 2018, JCI insight.

Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA

Marvin L. Thomas, B. Gamain, J. Shiloach, 2022, bioRxiv.

Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques

Charles Anderson, Z. Beck, G. Matyas, 2021, npj Vaccines.

Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques

Charles Anderson, Z. Beck, G. Matyas, 2021, NPJ vaccines.

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice

P. Scaria, B. Swihart, Yimin Wu, 2021, The Journal of clinical investigation.

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.

A. Dicko, O. Doumbo, M. Fay, 2009, Vaccine.

Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains

S. Reed, Lirong Shi, P. Sinnis, 2015, Infection and Immunity.

Composite active site of an ABC ATPase: MutS uses ATP to verify mismatch recognition and authorize DNA repair.

P. Hsieh, Wei Yang, G. Obmolova, 2001, Molecular cell.

Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA

T. Theander, P. Scaria, A. Salanti, 2023, Lab animal.

Phase 1 Study in Malaria Naı¨ve Adults of BSAM2/ Alhydrogel H + CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria

Yimin Wu, D. Narum, R. Ellis, 2022 .